Trial Profile
Global trial of PTG-300 in patients with myelodysplastic syndrome (MDS)
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2021
Price :
$35
*
At a glance
- Drugs Rusfertide (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 11 Oct 2021 According to a Protagonist Therapeutics media release, the company announced that the U.S. Food and Drug Administration (FDA) has removed the full clinical hold on the Companys rusfertide clinical studies. Per the FDA, dosing in all clinical studies of rusfertide may be resumed. The Company is working closely with study investigators and clinical trial sites to resume dosing of patients in ongoing clinical trials with rusfertide after patients have been reconsented.
- 17 Sep 2021 According to a Protagonist Therapeutics media release, the U.S. FDA have placed a clinical hold on clinical studies of rusfertide after a non-clinical finding in a 26-week rasH2 transgenic mouse model study, benign and malignant subcutaneous skin tumors were observed in the study. The dosing of patients in all ongoing clinical trials with rusfertide will be put on hold, and study investigators have been contacted to facilitate patient notification.
- 10 Mar 2020 According to a Protagonist Therapeutics media release, the company expects to initiate this trial in the first half of 2020.